AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati
NEW ORLEANS — Amgen attempted to further pull away from Mirati Therapeutics in the KRAS space, touting a new batch of long-term non-small cell lung cancer data at AACR for its approved drug Lumakras.
In a pooled dataset of 172 NSCLC patients from its Phase I and Phase II studies, Amgen reported an objective response rate of 40.7% after two years, including five complete responses and 65 partial responses. The big biotech also found that 32.5% of these patients survived after two years of treatment, and the median OS was 12.5 months with a median 24.9 months of follow-up.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.